Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from the EXPEDITE study of Remodulin® induction prior to Orenitram® therapy to be presented at ATS
Baseline patient data from the TETON studies of Tyvaso® Inhalation Solution in. | April 18, 2023
Blue Cross and Blue Shield of Vermont recognized for quality | Vermont Business Magazine vermontbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vermontbiz.com Daily Mail and Mail on Sunday newspapers.
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer s Association International Conference 2021
- Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer s disease
- Presentations include an assessment of the correlation between reductions in amyloid beta and other biomarkers of Alzheimer s disease and clinical decline after treatment with ADUHELM
- Presentation on ARIA data from Phase 3 trials provides insights for effective monitoring and management in real-world clinical practice
TOKYO, July 27, 2021 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer s Association International Conferen